1. Introduction {#sec1}
===============

Tuberculosis remains an important global health issue causing considerable morbidity and mortality. The development of *acute respiratory distress syndrome* (ARDS) is however rare \[[@bib1]\] and most often seen in disseminated disease (*miliary tuberculosis*) \[[@bib2],[@bib3]\]. Mortality rates for patients with tuberculosis who require mechanical ventilation are high (60--70%) \[[@bib3], [@bib4], [@bib5]\], higher than for any other cause of ARDS \[[@bib1]\]. Experience with the use of *extracorporeal membrane oxygenation* (ECMO) in this setting is limited, with only a handful of case-reports published \[[@bib6]\]. We present a case of miliary tuberculosis where prolonged ECMO therapy was successful but both diagnosis and treatment of the infection challenging.

2. Case presentation {#sec2}
====================

A previously healthy 18 year old male was admitted to hospital with a few days history of fever and shortness of breath. Chest X-ray showed bilateral interstitial infiltrates and empirical therapy for presumed community-acquired pneumonia was started. A more thorough history taking revealed symptoms of weight loss, lethargy and swallowing difficulties of three months duration. The patient was in hypoxic respiratory failure and therefore intubated within a few hours of admission. A *computed tomography* (CT) scan showed widespread nodular infiltrates and signs of an abscess in the mediastinum ([Fig. 1](#fig1){ref-type="fig"}). Later CT scans confirmed leakage of contrast medium from the oesophagus to the mediastinum but endoscopy did not reveal any obvious pathology.Fig. 1A CT scan the day after admission showing multiple nodular infiltrates. Mediastinal abscess not visible in this slide.Fig. 1

The patient was septic on admission and needed high-dose vasopressors. Hemodynamic instability resolved within few days but the respiratory failure did not. The patient received lung-protective mechanical ventilation for 18 days, with intermittent prone positioning. Initial cultures from bronchoalveolar lavage and viral polymerase chain reaction (PCR) assays were negative. Ziehl-Neelsen staining did not reveal acid-fast bacilli on repeated samples of tracheal aspirates. Interferon-ɣ release assay (IGRA) for tuberculosis was indeterminable. An extensive work-up regarding infectious, malignant and immunological causes was negative. Antibiotic therapy was expanded and the patient received empirical corticosteroids and immunoglobulins. At last transbronchial biopsies were taken with fiberoptic bronchoscopy guidance. Shortly after that intervention the patient developed bilateral tension pneumothoraces, pneumopericardium and subcutant emphysema ([Fig. 2](#fig2){ref-type="fig"}). Despite prompt drainage of both pleura, oxygenation of the patient became critical and *veno-venous ECMO* therapy was started.Fig. 2A CT scan after 18 days in the ICU. The patient developed bilateral pneumothoraces, pneumopericardium and pneumomediastinum after a trans-bronchial biopsy. Bilateral pleural tubes in-situ.Fig. 2

Microscopy of transbronchial biopsies revealed acid-fast bacilli and tuberculosis treatment was initiated with *rifampicin*, *isoniazide*, *ethambutol* and *pyrazinamide.* The diagnosis of miliary tuberculosis was later confirmed (26 days after admission) when growth of *Mycobacterium tuberculosis* was detected in samples taken at admission. The bacteria grew in tracheal aspirate, urine and cerebrospinal fluid. Additionally, granulomas were seen in a bone marrow aspirate, liver and lung biopsies. The bacteria was found to be susceptible to all first-line anti-tuberculosis agents. The patient\'s dysphagia and mediastinal abscess were probably related to tuberculosis in the mediastinum. During the ECMO treatment the patient\'s lungs developed multiple bullae and he had persistent pneumothoraces where the lungs did not expand despite patent pleural tubes ([Fig. 3](#fig3){ref-type="fig"}).Fig. 3A CT scan after two weeks on VV-ECMO. Both lungs show numerous bullae and there were persistent bilateral pneumothoraces despite pleural tubes in-situ.Fig. 3

Serum levels of anti-tuberculosis agents were monitored and levels of both isoniazid and rifampicin were repeatedly subtherapeutic despite escalating doses and a change to intravenous administration. After multiple negative samples, acid-fast bacilli were seen in tracheal aspirates on two occasions, four weeks after the start of treatment. During the VV-ECMO treatment, a multi-resistant *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* were repeatedly cultured from tracheal aspirates. These bacteria were successfully eradicated with a combination therapy of inhaled *colistin* and *tobramycin* along with intravenous *amikacin*, *meropenem* and *ceftazidime/avibactam.* As with the anti-tuberculosis agents, serum levels of *amikacin* were low.

After 45 days on ECMO the patient started to show signs of recovery with increasing lung compliance and re-expansion of the lungs ([Fig. 4](#fig4){ref-type="fig"}). He was successfully weaned from ECMO after 50 days. Complications during the ECMO run were thrombocytopenia, minor bleedings from puncture sites and sensory symptoms in lower limbs. The patient stayed a total of 76 days in the ICU. After three months of rehabilitation he was back at home and had resumed previous activities, including sports.Fig. 4A CT scan after 46 days on ECMO. Both lungs have expanded with functional lung tissue visible again. This correlated with improvement clinically.Fig. 4

3. Discussion {#sec3}
=============

The use of ECMO in ARDS has been increasing rapidly in recent years \[[@bib7]\] and indications may be expanding. We have described successful use of ECMO in miliary tuberculosis, even though the patient had two relative contraindications for ECMO (mechanical ventilation with a high FiO~2~ (0.75--1.0) for 18 days and an unknown diagnosis at the time) \[[@bib8]\]. The lack of data on the use of ECMO for tuberculosis made prognostication difficult. Since the patient was young, without co-morbidities and with a single-organ failure, the therapy was continued, even though no signs of recovery were discernible for weeks. Technological advances have made longer ECMO runs possible without complications and studies have shown equivalent outcome for patients with short and extended runs \[[@bib9]\].

Tuberculosis is a rare cause of ARDS, even in high burden regions \[[@bib2],[@bib10]\]. ARDS is most often seen in the disseminated form of the disease (*miliary*) \[[@bib2],[@bib3]\] which only 1--2% of all tuberculosis patients exhibit \[[@bib11],[@bib12]\]. Published case-series of miliary tuberculosis have shown that 3--10% of these patients develop ARDS \[[@bib11],[@bib13]\]. The clinical picture tends to be with prodromal symptoms (fever, anorexia) for weeks prior to a rapid deterioration \[[@bib2],[@bib3]\] and this might help to differentiate ARDS from tuberculosis from other causes of ARDS.

The diagnosis of miliary tuberculosis can be challenging when the infection has caused the development of ARDS. The classical miliary pattern may be absent on a chest X-ray in 50% of patients \[[@bib12]\] although computed tomography scans have a higher sensitivity. Waiting for positive cultures (2--6 weeks) is not practical in these critically ill patients. Rates of positive microscopy for acid-fast bacilli in sputum samples have been low (32%--36%) in case series of miliary tuberculosis \[[@bib11],[@bib13]\]. The yield of microscopy was similar on samples obtained with the aid of bronchoscopy (31%) but the diagnosis of tuberculosis was rapidly obtained in 79% of patients with the addition of transbronchial biopsies during bronchoscopy \[[@bib14]\]. Current guidelines recommend fiberoptic bronchoscopy in sputum negative patients with suspected miliary tuberculosis, and that sampling should include bronchial brushings and/or transbronchial biopsy, especially in critically ill patients \[[@bib15]\]. Newer molecular methods (PCR) on bronchoalveolar lavage have shown 60--80% sensitivity for tuberculosis in smear-negative patients \[[@bib16],[@bib17]\] and may be an alternative to transbronchial biopsies where available. Transbronchial biopsies are not without risks in this patient population as demonstrated in our case.

Successful eradication of tuberculosis is dependent on adequate blood levels of anti-tuberculosis drugs \[[@bib1]\]. The first-line agents (apart from rifampicin) are generally only available as oral preparations and thus dependent on adequate absorption from the gastrointestinal tract, which cannot be relied on in the critically ill. We did not reach therapeutic targets for two agents during the ECMO therapy. Subtherapeutic levels of these drugs while on ECMO have been reported before \[[@bib18]\]. The ECMO circuit increases the volume of distribution for drugs and there is evidence for substantial sequestration of drugs in the circuits \[[@bib19]\]. There is a general lack of guidelines on optimal drug dosing for patients on ECMO.

The development of pneumothorax is not uncommon in tuberculosis and the management of this during ECMO can be challenging, as pleural tube placement is frequently accompanied by bleeding. Current guidelines \[[@bib8]\] from the Extracorporeal Life Support Organization (ELSO) recommend drainage with continuous suction for symptomatic pneumothorax (\>50% of hemithorax, enlarging or with hemodynamic compromise). Inspiratory pressure on the ventilator should be kept low or even at zero until air leaks have sealed. Managing patients with ARDS on ECMO without a ventilator is an emerging approach \[[@bib20],[@bib21]\] that may be useful in cases like this but further studies are needed.

4. Conclusions {#sec4}
==============

We have reported a case where prolonged ECMO therapy allowed extensive lung injury from miliary tuberculosis to heal, with a good outcome for the patient. Both diagnosis and treatment of tuberculosis is complex in the intensive care setting.
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